Currently out of the existing stock ratings of Matt O'brien, 620 are a BUY (83.56%), 117 are a HOLD (15.77%), 5 are a SELL (0.67%).

Matt O'brien

Work Performance Price Targets & Ratings Chart

Analyst Matt O'brien, currently employed at PIPER SANDLER, carries an average stock price target met ratio of 63.98% that have a potential upside of 27.85% achieved within 168 days.

Matt O'brien’s has documented 1,531 price targets and ratings displayed on 54 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on TFX, Teleflex orporated at 01-Jul-2024.

Wall Street Analyst Matt O'brien

Analyst best performing recommendations are on RMED (RA MEDICAL SYSTEMS).
The best stock recommendation documented was for KRMD (REPRO MED SYSTEMS) at 1/25/2021. The price target of $4.5 was fulfilled within 1 day with a profit of $0.63 (12.28%) receiving and performance score of 122.81.

Average potential price target upside

ABMD ABIOMED ALGN Align Technology APEN Apollo Endosurgery APYX Apyx Medical ATEC Alphatec Holdings ATRC AtriCure AZYO Aziyo Biologics  BAX Baxter International BSX Boston Scientific Corp CNMD CONMED COO The Cooper Companies . Common Stock DXCM DexCom ELGX Endologix FNA Paragon 28 GKOS Glaukos Corp GMED Globus Medical HUMA Humacyte IART Integra LifeSciences Holdings ISRG Intuitive Surgical ITMR Itamar Medical Ltd KIDS Orthopediatrics Corp KRMD Repro Med Systems LIVN LivaNova PLC MDT Medtronic PLC MDXG MiMedx Group MIRO Miromatrix Medical MMSI Merit Medical Systems MOTS Motus GI Holdings NUVA NuVasive NVTR Nuvectra PODD Insulet RMED RA Medical Systems SGHT Sight Sciences SPNE SeaSpine Holdings Corp SRGA Surgalign Holdings STIM Neuronetics SYK Stryker TCMD Tactile Systems Technology TELA Tela Bio TFX Teleflex orporated TNDM Tandem Diabetes Care UTRS Minerva Surgical VRAY ViewRay WMGI Wright Medical Group N.V XENT Intersect ENT XRAY Dentsply Sirona ZBH Zimmer Biomet Holdings ZYXI Zynex CVRX CVRx CUTR Cutera RCEL Avita Medical Ltd RMD ResMed PEN Penumbra STAA STAAR Surgical Company

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

388

$6.98 (1.83%)

355

1 years 8 months 19 days ago

2/5 (40%)

$14.49 (3.88%)

88

Hold

380

$-1.02 (-0.27%)

235

1 years 8 months 19 days ago

1/2 (50%)

$6.49 (1.74%)

36

Hold

380

$-1.02 (-0.27%)

350

1 years 8 months 20 days ago

24/41 (58.54%)

$2.18 (0.58%)

138

Buy

300

$-81.02 (-21.26%)

425

1 years 9 months 9 days ago

1/2 (50%)

$57.23 (23.57%)

20

Sell

235

$-146.02 (-38.32%)

275

2 years 6 days ago

6/8 (75%)

$-33.23 (-12.39%)

142

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Matt O'brien is most bullish on?

Potential upside of $70.13 has been obtained for PEN (PENUMBRA)

Which stock is Matt O'brien is most reserved on?

Potential downside of -$2.5 has been obtained for STAA (STAAR SURGICAL COMPANY)

What Year was the first public recommendation made by Matt O'brien?

On 2014

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?